Evox eyes clinic for internal pipeline with £69.2M series C round

A £69.2 million ($95.4 million) series C led by Redmile Group gives Evox the funding it needs to bring its internal rare disease pipeline into the clinic as it forges ahead on pharma-partnered programs. 

Evox Therapeutics Ltd.’s DeliverEX platform engineers exosomes to deliver proteins and RNAs to specific tissues and areas of the body that are difficult for drugs to reach. Its lead candidates, EVX-102 and EVX-103, are slated to enter the clinic in 2022 for urea cycle disorders. ...